Cargando…
Tuberculous Drug-induced Liver Injury and Treatment Re-challenge in Human Immunodeficiency Virus Co-infection
BACKGROUND: Tuberculosis drug-induced liver injury (TB-DILI) is the most common adverse event necessitating therapy interruption. The optimal re-challenge strategy for antituberculous therapy (ATT) remains unclear, especially in human immunodeficiency virus (HIV) co-infected individuals in high-prev...
Autores principales: | Costiniuk, Cecilia T., Gosnell, Bernadett I., Manzini, Thandekile C., Du Plessis, Camille N., Moosa, Mahomed Yunus S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693306/ https://www.ncbi.nlm.nih.gov/pubmed/26752869 http://dx.doi.org/10.4103/0974-777X.170499 |
Ejemplares similares
-
A case series of emtricitabine-induced pure red cell aplasia
por: Manickchund, Nithendra, et al.
Publicado: (2021) -
Emtricitabine-induced pure red cell aplasia
por: Manickchund, Nithendra, et al.
Publicado: (2019) -
Challenges in the Management of Disseminated Progressive Histoplasmosis in Human Immunodeficiency Virus-Infected Patients in Resource-Limited Settings
por: Murphy, Richard A., et al.
Publicado: (2015) -
Relationship of Human Immunodeficiency Virus Viral Load in Cerebrospinal Fluid and Plasma in Patients Co-infected With Cryptococcal Meningitis
por: Chang, Christina C., et al.
Publicado: (2017) -
A systematic review of hepatic tuberculosis with considerations in human immunodeficiency virus co-infection
por: Hickey, Andrew J, et al.
Publicado: (2015)